ESMO Sep 13, 2022 Nearly all dMMR Colon Cancer Patients Respond in Trial of Neoadjuvant Opdivo-Yervoy Premium Sep 12, 2022 ESMO Data Sharpens View of How Grail, Exact Sciences Multi-Cancer Early Detection Tests Perform Premium Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Sep 11, 2022 Selective Estrogen Receptor Degraders, Modulators Show Promise in ESR1-Mutant Breast Cancer Premium Sep 11, 2022 PD-L1 Test Comparison Finds Varying Ability to ID Bladder Cancer Patients Who Benefit From Tecentriq Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Sep 11, 2022 ESMO Study Explores Role of Air Pollution in EGFR-Mutant NSCLC in Non-Smokers Premium Sep 10, 2022 Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer Premium Sep 10, 2022 Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Jul 7, 2022 ESMO Releases Guidelines for Liquid Biopsy Testing in Cancer Patients May 12, 2022 ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making Premium May 4, 2022 ESMO Breast Cancer Symposium Data Support First-Line CDK4/6 Inhibitor Combinations Premium Mar 17, 2022 Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing Premium Sep 23, 2021 European Society for Medical Oncology Congress 2021: Precision Oncology Data Roundup Sep 23, 2021 ESMO Oncologists Debate Optimal Timing for Broad NGS, Align on Key Barriers to Precision Oncology Premium Sep 22, 2021 Rain Therapeutics' Milademetan Shows Clinical Activity in MDM2-Amplified Intimal Sarcoma Sep 21, 2021 ESMO Study Identifies Potential Predictive Biomarkers to ID TNBC Patients for Therapy De-Escalation Sep 21, 2021 Early ESMO Data Show Interferon Signature's Ability to Guide Neoadjuvant Melanoma Immunotherapy Sep 21, 2021 Oncologists Bemoan 'Lousy' PD-L1 Biomarker in Light of New Adjuvant Tecentriq NSCLC Study Data Premium Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
